Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as R906289 Monosodium (R289 Na)
R906289 Monosodium · 1 trial · 1 indication
* Incidence of adverse events (AEs) * Incidence of discontinuation or interruptions of R289 due to AEs * Incidence of dose limiting toxicities (DLTs)
| Arm | Type | Description |
|---|---|---|
| Experimental | EXPERIMENTAL | ESCALATION PHASE: Dose Level 1: 250mg PO qd Dose Level 2: 500mg PO qd Dose Level 3: 750 mg PO qd Dose Level 4: 250 mg PO bid Dose Level 5: 500 mg PO AM/250 mg PO PM Dose Level 6: 500 mg PO bid EXPANSION PHASE (randomized 1:1): Dose Level 1: 250 mg PO qd Dose Level 2: 250 mg PO bid |
| Name | Type | Description |
|---|---|---|
| R906289 Monosodium (R289 Na) | DRUG | Drug: R906289 Monosodium (R289 Na) R906289 Monosodium (250mg PO qd, 250mg PO bid, 500 mg PO qd, 500 mg PO bid, 750 mg PO qd, split dose - 500 mg PO AM/250 mg PO PM) |
Inclusion Criteria: * Patient must be ≥ 18 years of age at the time of signing the informed consent. * Must have definitive diagnosis of MDS with very low, low, or intermediate-1 risk (International Prognostic Scoring System (IPSS)-R ≤ 3.5) and ≤5% bone marrow myeloblasts. * Must be relapsed, refra...
Top 20 of 34 competitors
R906289 Monosodium is an investigational small molecule being studied for the treatment of Low Risk Myelodysplastic Syndromes. It is currently in Phase 1 clinical development, with an active trial recruiting patients in the United States. The drug has not been approved by the FDA and remains under clinical investigation.
R906289 Monosodium is being developed by Rigel Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker RIGL. The company is conducting a Phase 1 clinical trial to evaluate the drug in patients with Low Risk Myelodysplastic Syndromes.
R906289 Monosodium is in Phase 1 clinical development. It is being evaluated in an ongoing, uncontrolled trial for Low Risk Myelodysplastic Syndromes. The drug is investigational and has not received FDA approval. The Phase 1 study is currently recruiting participants in the United States.
R906289 Monosodium is being studied in clinical trial NCT05308264, titled 'Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)'. This Phase 1 trial is recruiting 86 participants aged 18 years and older in the United States. The study is uncontrolled and not blinded.
Yes, R906289 Monosodium is also known as R289 Na. Both names refer to the same investigational drug being developed by Rigel Pharmaceuticals for Low Risk Myelodysplastic Syndromes. The drug is currently in Phase 1 clinical trials under the identifier NCT05308264.